Dr John Hart
Dr John Hart
Details
Role
Senior Research Fellow
Research area
Infection, Immunity and Global Health
Group
Tropical Diseases
John Hart is a medical epidemiologist with a background in tropical medicine and international health. He has extensive experience in research projects and trials in sub-Saharan Africa and Asia. His current interests are in azithromycin mass drug administration for reducing child mortality, and vaccination in vulnerable children.
John Hart is a medical epidemiologist with a background in tropical medicine and international health. He has extensive experience in research projects and trials in sub-Saharan Africa and Asia. His current interests are in azithromycin mass drug...
John Hart is a medical epidemiologist with a background in tropical medicine and international health. He has extensive experience in research projects and trials in sub-Saharan Africa and Asia. His current interests are in azithromycin mass drug administration for reducing child mortality, and vaccination in vulnerable children.
Top Publications
- Chaima, D, Hart, J, Pickering, H, Burr, S, Maleta, K, Kalua, K, Bailey, R, Holland, M. Association between intestinal bacterial carriage, biomarkers of environmental enteric dysfunction, and stunting in rural Malawian children. 2024 view publication
- Chaima, D, Pickering, H, Hart, JD, Burr, SE, Maleta, KM, Kalua, K, Bailey, RL, Holland, MJ. Fecal biomarkers of environmental enteric dysfunction and the gut microbiota of rural Malawian children: an observational study. 2024 view publication
- Gladstone, RA, Bojang, E, Hart, J, Harding-Esch, EM, Mabey, D, Sillah, A, Bailey, RL, Burr, SE, Roca, A, Bentley, SD, et al. Mass drug administration with azithromycin for trachoma elimination and the population structure of Streptococcus pneumoniae in the nasopharynx. 2024 view publication
- Batmunkh, T, Moore, KA, Thomson, H, Altangerel, B, Amraa, O, Avaa, N, Batbayar, L, Batsukh, K, Bright, K, Burentogtokh, T, et al. Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.. Lancet Reg Health West Pac 42: 100953 2024 view publication
- Hart, JD, Ong, DS, Chokephaibulkit, K, Ong-Lim, AT, Vereti, I, Crawford, NW, Russell, F. Considerations for vaccinating children against COVID-19.. BMJ Paediatr Open 7(1) : 2023 view publication
Page 1 of 9
Career information
Share //
